跳至主導覽 跳至搜尋 跳過主要內容

Nivolumab safety and efficacy in advanced, platinum-resistant, non-small cell lung cancer, radical radiotherapy-ineligible patients: A phase II study in Taiwan

  • Yuh Min Chen
  • , James Chih-Hsin Yang
  • , Wu Chou Su
  • , Inn Wen Chong
  • , Te Chun Hsia
  • , Meng Chih Lin
  • , Gee Chen Chang
  • , Chao Hua Chiu
  • , Chao Chi Ho
  • , Shang Yin Wu
  • , Jen Yu Hung
  • , Chin Chou Wang
  • , Tsung Ying Yang
  • , Chong Jen Yu*
  • *此作品的通信作者
  • National Yang Ming Chiao Tung University
  • Veterans General Hospital-Taipei
  • National Taiwan University
  • National Cheng Kung University
  • Kaohsiung Medical University
  • China Medical University Taichung
  • Chang Gung Memorial Hospital
  • Chang Gung University
  • Veterans General Hospital-Taichung Taiwan

研究成果: 期刊稿件 › 文章 › 同儕審查

10 引文 斯高帕斯(Scopus)

摘要

Background/Purpose: There is a lack of data on nivolumab treatment outcomes in Taiwanese patients with advanced or recurrent non-small cell lung cancer (NSCLC) ineligible for radical radiotherapy and resistant to platinum-based chemotherapy. We investigated the safety and efficacy of nivolumab in this population. Methods: In this ongoing, multicenter, open-label, single-arm, phase II study, patients aged ≥20 years with a performance status of 0–1 and stage IIIB/IV or recurrent NSCLC received nivolumab 3 mg/kg every 2 weeks in 6-week cycles. Interim data obtained between 27 January 2016 and 21 May 2017 were analyzed. Safety, based on adverse event (AE) reporting, was the primary endpoint. Efficacy assessment parameters included overall response rate (ORR), overall survival (OS), and progression-free survival (PFS). Results: Among 53 treated patients with advanced NSCLC (median age 61.0 years; 62.3% male), mean treatment duration was 99.7 days. AEs (any grade) and serious AEs were reported by 92.5% and 47.2% of patients, respectively. Adverse drug reactions (ADRs; any) occurred in 58.5% of patients; grade ≥3 ADRs occurred in 13.2% of patients. Five deaths occurred; two cases (neoplasm progression and septic shock) were considered treatment-emergent. Common ADRs were fatigue (17.0%) and rash (13.2%). Common immune-related treatment-emergent AEs were rash (17.0%) and pruritus (13.2%). The centrally assessed ORR was 9.4% (5/53). The median OS and median PFS were 11.5 months and 1.4 months, respectively. Conclusion: Nivolumab appeared to be safe and effective in Taiwanese patients. These interim results suggest that nivolumab is a suitable treatment option for this population. Clinical trial registration: NCT02582125.

原文英語
頁(從 - 到)1817-1826
頁數10
期刊Journal of the Formosan Medical Association
卷119
發行號12
DOIs
出版品狀態已出版 - 12 2020
對外發佈是

文獻附註

Publisher Copyright:
© 2020

UN SDG

此研究成果有助於以下永續發展目標

  1. SDG3 健康與福祉
    SDG3 健康與福祉

指紋

深入研究「Nivolumab safety and efficacy in advanced, platinum-resistant, non-small cell lung cancer, radical radiotherapy-ineligible patients: A phase II study in Taiwan」主題。共同形成了獨特的指紋。

引用此